Dossier assessment

Axicabtagene ciloleucel (follicular lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V

Status
Status: Withdrawn commission
Project no.
G22-40
Last updated

Project details

Project no.
G22-40
Commission
Commission awarded on 15.11.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Withdrawn commission
Department/Division
Health Economics
Topic
Cancer
Note

In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.

Connected Projects

  1. Dossier assessment

    Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G18-18
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Axicabtagene ciloleucel (B-cell lymphoma PMBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G18-19
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Axicabtagene ciloleucel (DLBCL and HGBL) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V

    Project no.
    G22-39
    Last updated

    Status: Withdrawn commission

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form